New expensive treatments for hepatitis C infection.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

29 citing papers in PubMed.

1. Peer-Assisted Telemedicine for Hepatitis C (PATHS): Process evaluation results from a State Opioid Response-funded program.Journal of substance use and addiction treatment · 2024
   Article
2. Value appropriation in hepatitis C.The European journal of health economics : HEPAC : health economics in prevention and care · 2022
   Article
3. Association of Direct-Acting Antiviral Treatment With Mortality Among Medicare Beneficiaries With Hepatitis C.JAMA network open · 2020
   Article
4. Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral Therapy.Frontiers in pharmacology · 2020
   Article
5. Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates.Applied health economics and health policy · 2018
   Article
6. Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.Journal of clinical gastroenterology · 2018
   Observational
7. Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden.European journal of clinical pharmacology · 2018
   Article
8. Newly Diagnosed Hepatitis C in the US Commercially Insured Population Before and After the 2012 Implementation of Expanded Screening Guidelines.American health & drug benefits · 2018
   Article
9. Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.Frontiers in public health · 2018
   Review
10. Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review.Journal of clinical and translational hepatology · 2017
    Review
11. Restrictions of Hepatitis C Treatment for Substance-Using Medicaid Patients: Cost Versus Ethics.American journal of public health · 2017
    Article
12. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.BMC health services research · 2017
    Article
13. Pharmacy Benefit Management Companies: Do They Create Value in the US Healthcare System?PharmacoEconomics · 2017
    Article
14. Estimating the Effect of Health Insurance on Personal Prescription Drug Importation.Medical care research and review : MCRR · 2017
    Article
15. Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease.Clinical drug investigation · 2017
    Article
16. Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2016
    Article
17. Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study.Journal of managed care & specialty pharmacy · 2016
    Article
18. Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways.Frontiers in pharmacology · 2016
    Article
19. The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?PloS one · 2016
    Article
20. How to Fairly Allocate Scarce Medical Resources: Ethical Argumentation under Scrutiny by Health Professionals and Lay People.PloS one · 2016
    Article

Corrections and comments

• Commented on by
  Costs of new treatments for hepatitis C infection.2014
• Commented on by
  Costs of new treatments for hepatitis C infection.2014
• Commented on by
  Costs of new treatments for hepatitis C infection--reply.2014
• Commented on by
  Does Insulin Price Reduction Suggest a Path Forward for Lowering Drug Costs?2023

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as